Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP

Abstract Twenty percent of patients with high‐tumor‐burden (HTB) follicular lymphoma (FL) develop progression/relapse of disease (POD) within 24 months of frontline immunochemotherapy. Unfortunately, about 50% of these patients die within 5 years since POD event. Rituximab maintenance was proven to...

Full description

Bibliographic Details
Main Authors: Vít Procházka, David Belada, Andrea Janíková, Kateřina Benešová, Heidi Mociková, Juraj Ďuraš, Jan Pirnos, Kateřina Kopečková, Vít Campr, Tomáš Fürst, Robert Pytlík, Alice Sýkorová, Jozef Michalka, Jitka Dlouhá, Tomáš Papajík, Marek Trněný
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:eJHaem
Subjects:
early progression
follicular lymphoma
maintenance
rituximab
Online Access:https://doi.org/10.1002/jha2.60

Similar Items

Similar Items